中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

48 records (took 0.022 seconds)

    AN ANTI-CANCER CYTOTOXIC MONOCLONAL ANTIBODY
    1.
    发明申请
    AN ANTI-CANCER CYTOTOXIC MONOCLONAL ANTIBODY 审中-公开
    抗癌细胞毒性单克隆抗体

    公开(公告)号：WO2009009882A1

    公开(公告)日：2009-01-22

    申请号：PCT/CA2008/001289

    申请日：2008-07-14

    Applicant: ARIUS RESEARCH INC. ,  YOUNG, David, S., F. ,  FINDLAY, Helen, P. ,  HAHN, Susan, E.

    Inventor： YOUNG, David, S., F. ,  FINDLAY, Helen, P. ,  HAHN, Susan, E.

    IPC: C07K16/30 ,  A61K39/395 ,  A61K47/48 ,  A61K51/10 ,  A61P35/00 ,  A61P37/04 ,  C07K16/18 ,  C07K16/28 ,  C07K16/46 ,  C07K19/00 ,  C12N5/16 ,  C12P21/08 ,  G01N33/53 ,  G01N33/574 ,  G01N33/577

    CPC classification number: G01N33/57484 ,  A61K47/6857 ,  A61K51/1054 ,  A61K2039/505 ,  C07K16/3023

    Abstract: Antibody mediated killing of cancer cells is an effective approach to treat cancer. Antibodies generated in mice, upon immunization with lung adenocarcinoma cells, are screened for cytotoxicity against a variety of cancer cell lines as the endpomt. An anti-cancer cytotoxic monoclonal antibody is isolated, produced by the hybπdoma AR92A271.7 deposited with IDAC as Accession Number 290507-04, which is cytotoxic to a lung cancer cell line and reduces tumor burden in an animal model of human lung cancer. The monoclonal antibody also binds to several cancer cell lines. There is low, but detectable, binding of the monoclonal antibody to a non-cancer cell line, however, cytotoxicity is not induced in this non-cancer cell line. This monoclonal antibody can be used to aid staging and diagnosis of cancer, and in the treatment of primary tumors and tumor metastases. This cytotoxic monoclonal antibody can also be used to deliver toxins, enzymes, radioactive compounds and hematogenous cells to cancer cells, to further aid reduction of tumor burden.

    Abstract translation: 抗体介导的杀死癌细胞是治疗癌症的有效方法。 在用肺腺癌细胞免疫后，在小鼠中产生的抗体作为内生物被筛选为对各种癌细胞系的细胞毒性。 分离抗癌细胞毒性单克隆抗体，其由沉积有IDAC的登录号290507-04的hybpdoma AR92A271.7产生，其对肺癌细胞系具有细胞毒性，并降低人肺癌动物模型中的肿瘤负荷。 单克隆抗体也与几种癌细胞系结合。 单克隆抗体与非癌细胞系具有低但可检测的结合，然而，在该非癌细胞系中不诱导细胞毒性。 该单克隆抗体可用于帮助癌症的分期和诊断，以及原发性肿瘤和肿瘤转移的治疗。 这种细胞毒性单克隆抗体也可用于向癌细胞输送毒素，酶，放射性化合物和血液细胞，以进一步有助于减少肿瘤负担。

    AN ANTI-CANCER CYTOTOXIC MONOCLONAL ANTIBODY
    2.
    发明申请
    AN ANTI-CANCER CYTOTOXIC MONOCLONAL ANTIBODY 审中-公开
    抗癌细胞毒性单克隆抗体

    公开(公告)号：WO2009009881A1

    公开(公告)日：2009-01-22

    申请号：PCT/CA2008/001288

    申请日：2008-07-14

    Applicant: ARIUS RESEARCH INC.

    Inventor： YOUNG, David, S. F. ,  FINDLAY, Helen, P. ,  HAHN, Susan, E. ,  CECHETTO, Lisa, M.

    IPC: C07K16/30 ,  A61K39/395 ,  A61K47/48 ,  A61K51/10 ,  A61P35/00 ,  A61P37/04 ,  C07K16/28 ,  C07K16/46 ,  C07K19/00 ,  C12N5/16 ,  C12P21/08 ,  G01N33/574 ,  G01N33/577

    CPC classification number: G01N33/57484 ,  A61K47/6869 ,  A61K51/1072 ,  A61K2039/505 ,  C07K16/3069

    Abstract: Antibody mediated killing of cancer cells is an effective approach to treat cancer Antibodies generated in mice, upon immunization with ovarian cancer cells, are screened for cytotoxicity against a variety of cancer cell lines as the endpomt An anti-cancer cytotoxic monoclonal antibody is isolated, produced by the hybπdoma AR104A1289 2 2 deposited with IDAC as Accession Number 190607-04, which is cytotoxic to a colon cancer cell line, and reduces tumor burden in animal models of human pancreatic, breast and prostate cancer The monoclonal antibody also binds to several cancer cell lines The monoclonal antibody does not cause cytotoxicity to a non-cancer cell line, though it binds the cell line This monoclonal antibody can be used to aid staging and diagnosis of cancer, and in the treatment of primary tumors and tumor metastases This cytotoxic monoclonal antibody can also be used to deliver toxms, enzymes, radioactive compounds and hematogenous cells to cancer cells, to further aid reduction of tumor burden.

    Abstract translation: 抗体介导的杀死癌细胞是治疗癌症的有效方法当卵巢癌细胞免疫后，小鼠产生的抗体被筛选，作为内切生物对各种癌细胞系的细胞毒性分离抗生素细胞毒性单克隆抗体 由编号为190607-04的IDAC作为保藏号为190607-04的hybpdoma AR104A1289 2 2，其对结肠癌细胞系具有细胞毒性，并且降低人胰腺，乳腺和前列腺癌动物模型中的肿瘤负荷。单克隆抗体还结合多种癌细胞 线尽管它与细胞系结合，单克隆抗体对非癌细胞系不产生细胞毒性该单克隆抗体可用于帮助癌症的分期和诊断，以及原发性肿瘤和肿瘤转移的治疗。该细胞毒性单克隆抗体 也可用于向癌细胞递送毒素，酶，放射性化合物和血细胞，以进一步减少 肿瘤负担。

    CANCEROUS DISEASE MODIFYING ANTIBODIES
    5.
    发明申请
    CANCEROUS DISEASE MODIFYING ANTIBODIES 审中-公开

    公开(公告)号：WO2007014457A1

    公开(公告)日：2007-02-08

    申请号：PCT/CA2006/001248

    申请日：2006-08-01

    Applicant: ARIUS RESEARCH, INC.

    Inventor： YOUNG, David, S., F. ,  HAHN, Susan, E. ,  CECHETTO, Lisa, M.

    IPC: C12P21/08 ,  A61P35/00 ,  A61K39/395 ,  C07K16/18 ,  C07K16/30 ,  C07K16/46 ,  C12N5/16 ,  G01N33/567 ,  G01N33/574

    CPC classification number: G01N33/57492 ,  A61K2039/505 ,  C07K16/30 ,  C07K16/3069 ,  C07K2317/73

    Abstract: The present invention relates to a method for producing patient cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can be used in aid of staging and diagnosis of a cancer, and can be used to treat primary tumors and tumor metastases. The anti-cancer antibodies can be conjugated to toxins, enzymes, radioactive compounds, and hematogenous cells.

    Abstract translation: 本发明涉及使用新的筛选范例来生产患者癌症疾病修饰抗体的方法。 通过使用癌细胞细胞毒性分离抗癌抗体作为终点，该方法使得可能产生用于治疗和诊断目的的抗癌抗体。 抗体可用于帮助分期和诊断癌症，并可用于治疗原发性肿瘤和肿瘤转移。 抗癌抗体可以与毒素，酶，放射性化合物和血细胞结合。

    CANCEROUS DISEASE MODIFYING ANTIBODIES
    8.
    发明申请
    CANCEROUS DISEASE MODIFYING ANTIBODIES 审中-公开

    公开(公告)号：WO2004065421A1

    公开(公告)日：2004-08-05

    申请号：PCT/CA2004/000058

    申请日：2004-01-19

    Applicant: ARIUS RESEARCH, INC.

    Inventor： YOUNG, David, S., F. ,  HAHN, Susan, E.

    IPC: C07K16/30

    CPC classification number: C07K16/30 ,  G01N33/574

    Abstract: The present invention relates to a method for producing patient cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can be used in aid of staging and diagnosis of a cancer, and can be used to treat primary tumors and tumor metastases. The anti-cancer antibodies can be conjugated to toxins, enzymes, radioactive compounds, and hematogenous cells.

    Abstract translation: 本发明涉及使用新的筛选范例来生产患者癌症疾病修饰抗体的方法。 通过使用癌细胞细胞毒性分离抗癌抗体作为终点，该方法使得可能产生用于治疗和诊断目的的抗癌抗体。 抗体可用于帮助分期和诊断癌症，并可用于治疗原发性肿瘤和肿瘤转移。 抗癌抗体可以与毒素，酶，放射性化合物和血细胞结合。

    HUMANIZED AND CHIMERIC ANTI-TROP-2 ANTIBODIES THAT MEDIATE CANCER CELL CYTOTOXICITY
    9.
    发明申请
    HUMANIZED AND CHIMERIC ANTI-TROP-2 ANTIBODIES THAT MEDIATE CANCER CELL CYTOTOXICITY 审中-公开
    媒介癌细胞毒性的人类和半抗原-2抗体

    公开(公告)号：WO2008144891A1

    公开(公告)日：2008-12-04

    申请号：PCT/CA2008/000979

    申请日：2008-05-23

    Applicant: ARIUS RESEARCH INC.

    Inventor： YOUNG, David, S., F. ,  FINDLAY, Helen P. ,  HAHN, Susan, E. ,  DA CRUZ, Luis, A., G. ,  FERRY, Alison, L.

    IPC: C07K16/30 ,  A61K39/395 ,  A61K47/48 ,  A61K51/10 ,  A61P35/00 ,  A61P37/04 ,  C07K16/28 ,  C07K16/46 ,  C12P21/08 ,  G01N33/574 ,  G01N33/577

    CPC classification number: G01N33/574 ,  A61K2039/505 ,  A61K2039/545 ,  C07K16/30 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/56 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/92

    Abstract: Expression of TROP-2, an approximately 35 kDa transmembrane protein and a substrate of protein kinase C, has been linked to several cancers. TROP-2 is also known as GA733-1, epithelial glycoprotein 1 (EGP-I) and tumor-associated calcium signal transducer-2. A monoclonal antibody against TROP-2 from the hybridoma AR47A6.4.2, deposited with the International Depository Authority of Canada (IDAC) as accession number 141205-05, was previously shown to be a cancerous disease modifying antibody (CDMAB), preventing tumour growth and reducing tumour burden in several cancer models including prostate, pancreatic and breast cancer by cytotoxicity. The variable regions of this monoclonal antibody were also isolated, sequenced and complementarity determining regions (CDRs) determined. Now, a chimeric antibody and humanized antibodies are generated that have similar TROP-2 binding activity as the parent 141205-05 monoclonal antibody. The monoclonal, chimeric and humanized antibodies can be conjugated to toxins, enzymes, radioactive compounds, cytokines, interferons, target or reporter moieties and hematogenous cells to treat cancer. These antibodies are also used in binding assays to determine TROP-2 expression on cells.

    Abstract translation: TROP-2（一种约35kDa的跨膜蛋白和蛋白激酶C的底物）的表达与几种癌症有关。 TROP-2也称为GA733-1，上皮糖蛋白1（EGP-1）和肿瘤相关钙信号转导-2。 保藏于加拿大国际保藏机构（IDAC）的保藏号为141205-05的来自杂交瘤AR47A6.4.2的TROP-2的单克隆抗体以前被证明是癌症疾病修饰抗体（CDMAB），预防肿瘤生长， 通过细胞毒性减少包括前列腺癌，胰腺癌和乳腺癌在内的几种癌症模型的肿瘤负荷。 该单克隆抗体的可变区也被分离，测序并确定互补决定区（CDR）。 现在，产生与母体141205-05单克隆抗体具有相似的TROP-2结合活性的嵌合抗体和人源化抗体。 单克隆，嵌合和人源化抗体可以与毒素，酶，放射性化合物，细胞因子，干扰素，靶或报告物部分和血源性细胞缀合以治疗癌症。 这些抗体也用于结合测定以确定细胞上的TROP-2表达。

Patent Agency Ranking